

PRODUCT INFORMATION




SNX-2112

Item No. 22359

CAS Registry No.: 908112-43-6
Formal Name: 2-[[*trans*-4-hydroxycyclohexyl]amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]-benzamide

Synonym: PF-04928473
MF: C₂₃H₂₇F₃N₄O₃
FW: 464.5
Purity: ≥98%
UV/Vis.: λ_{max}: 251, 360 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SNX-2112 is supplied as a crystalline solid. A stock solution may be made by dissolving the SNX-2112 in the solvent of choice. SNX-2112 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of SNX-2112 in these solvents is approximately 1 and 0.25 mg/ml, respectively.

SNX-2112 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SNX-2112 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SNX-2112 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SNX-2112 is a potent inhibitor of heat shock protein 90 (Hsp90) with a K_d value of 30 nM.¹ *In vitro*, SNX-2112 induces down-regulation of the client proteins HER2 and Akt. It inhibits proliferation in a panel of cancer cell lines (IC₅₀s = 10-50 nM). SNX-2112 (150 mg/kg) completely inhibits tumor growth in a BT474 breast cancer mouse xenograft model. SNX-2112 is also the active metabolite of prodrug SNX-5542 and preferentially accumulates in tumor tissue of mice treated with a single oral dose of 75 mg/kg SNX-5542. Formulations containing SNX-2112 are under clinical investigation for treatment of refractory solid tumors.²

References

- Chandarlapaty, S., Sawai, A., Ye, Q., *et al.* SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. *Clin. Cancer Res.* **14**(1), 240-248 (2008).
- Infante, J.R., Weiss, G.J., Jones, S., *et al.* Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. *Eur. J. Cancer* **50**(17), 2897-2904 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM